BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 21306243)

  • 21. Novel agents in gastroenteropancreatic neuroendocrine tumors.
    Stevenson R; Libutti SK; Saif MW
    JOP; 2013 Mar; 14(2):152-4. PubMed ID: 23474560
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.
    Tijeras-Raballand A; Neuzillet C; Couvelard A; Serova M; de Gramont A; Hammel P; Raymond E; Faivre S
    Target Oncol; 2012 Sep; 7(3):173-81. PubMed ID: 22923165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Everolimus for the treatment of pancreatic neuroendocrine tumors.
    Feldmann G; Bisht S; Schütte U; Haarmann J; Brossart P
    Expert Opin Pharmacother; 2012 Oct; 13(14):2073-84. PubMed ID: 22873789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States.
    Casciano R; Chulikavit M; Perrin A; Liu Z; Wang X; Garrison LP
    J Med Econ; 2012; 15 Suppl 1():55-64. PubMed ID: 22881362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New strategies for advanced neuroendocrine tumors in the era of targeted therapy.
    Dong M; Phan AT; Yao JC
    Clin Cancer Res; 2012 Apr; 18(7):1830-6. PubMed ID: 22338018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
    Raymond E; Dahan L; Raoul JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; Metrakos P; Smith D; Vinik A; Chen JS; Hörsch D; Hammel P; Wiedenmann B; Van Cutsem E; Patyna S; Lu DR; Blanckmeister C; Chao R; Ruszniewski P
    N Engl J Med; 2011 Feb; 364(6):501-13. PubMed ID: 21306237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment.
    Iacovelli R; Palazzo A; Trenta P; Mezi S; Pellegrino D; Naso G; Cortesi E
    Am J Clin Oncol; 2014 Dec; 37(6):611-5. PubMed ID: 23388560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors.
    Capdevila J; Tabernero J
    Cancer Discov; 2011 Aug; 1(3):213-21. PubMed ID: 22586573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pneumocystis jirovecii pneumonia under everolimus in two patients with metastatic pancreatic neuroendocrine tumors.
    Carbonnaux M; Molin Y; Souquet PJ; Tantin A; Lombard-Bohas C; Walter T
    Invest New Drugs; 2014 Dec; 32(6):1308-10. PubMed ID: 25119297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in pancreatic neuroendocrine tumor treatment.
    Castellano D; Grande E; Barriuso J
    N Engl J Med; 2011 May; 364(19):1872-3; author reply 1873-4. PubMed ID: 21561356
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment: symptomatic treatment of hypoglycaemia.
    Tabarin A; Goichot B;
    Ann Endocrinol (Paris); 2013 Jul; 74(3):196-9. PubMed ID: 23791453
    [No Abstract]   [Full Text] [Related]  

  • 32. Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.
    Thompson LA; Kim M; Wenger SD; O'Bryant CL
    Ann Pharmacother; 2012 Sep; 46(9):1212-9. PubMed ID: 22947595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Molecular targeted drugs for soft tissue sarcoma and neuroendocrine tumor].
    Kato S
    Nihon Rinsho; 2015 Aug; 73(8):1398-402. PubMed ID: 26281696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in the treatment of gastroenteropancreatic neuroendocrine tumors.
    Phan AT
    Clin Adv Hematol Oncol; 2014 Dec; 12(12 Suppl 19):3-5. PubMed ID: 25768101
    [No Abstract]   [Full Text] [Related]  

  • 35. Steve Jobs's cancer. Pancreatic neuroendocrine tumors are becoming more common (the bad news) and also more treatable (the good news).
    Harv Health Lett; 2012 Jan; 37(3):1-3. PubMed ID: 22400158
    [No Abstract]   [Full Text] [Related]  

  • 36. Pancreatic NETs: where do we stand now?
    Faivre S; Castellano D; Strosberg J; González E; Salazar R
    Cancer Metastasis Rev; 2014 Mar; 33(1):361-6. PubMed ID: 24452757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Recent progress in the molecular-targeting treatment of neuroendocrine tumors].
    Unno M
    Nihon Shokakibyo Gakkai Zasshi; 2010 Mar; 107(3):392-5. PubMed ID: 20203442
    [No Abstract]   [Full Text] [Related]  

  • 38. [Current status and therapeutic strategy for pancreatic neuroendocrine tumors in Japan].
    Ito T; Igarashi H; Jensen RT; Takayanagi R
    Fukuoka Igaku Zasshi; 2012 Jul; 103(7):131-7. PubMed ID: 22978065
    [No Abstract]   [Full Text] [Related]  

  • 39. Translational medicine: Cancer lessons from mice to humans.
    Tuveson D; Hanahan D
    Nature; 2011 Mar; 471(7338):316-7. PubMed ID: 21412332
    [No Abstract]   [Full Text] [Related]  

  • 40. Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.
    Martins D; Spada F; Lambrescu I; Rubino M; Cella C; Gibelli B; Grana C; Ribero D; Bertani E; Ravizza D; Bonomo G; Funicelli L; Pisa E; Zerini D; Fazio N;
    Target Oncol; 2017 Oct; 12(5):611-622. PubMed ID: 28634872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.